Leadhexa Biotechnologies Overview

  • Founded
  • 2014
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Leadhexa Biotechnologies General Information


Developer of molecular technology designed to discovered enzyme Manganese Superoxide Dismutase. The company's technology demonstrated efficacy in numerous preclinical models including actinic keratosis, radiation protection, protection of kidney damage due to cyclosporine, liver cirrhosis and liver ischemia-reperfusion injury, enabling doctors to remove supra-stoichiometric amounts of reactive oxygen species to enter in the Mitochondria and cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Primary Office
  • 953 Indiana Street
  • San Francisco, CA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Leadhexa Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Jan-2015 Completed Out of Business
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Leadhexa Biotechnologies’s complete valuation and funding history, request access »

Leadhexa Biotechnologies Executive Team (3)

Name Title Board Seat Contact Info
Aldo Mancini Co-Founder, Chief Executive Officer & President
Francesco Ambesi-Impiombato Co-Founder
Roberto Mancini MD Researcher
To view Leadhexa Biotechnologies’s complete executive team members history, request access »